286
Participants
Start Date
May 15, 2018
Primary Completion Date
October 6, 2020
Study Completion Date
October 6, 2020
Naloxone, intranasal
"Active compound naloxone 14 mg/ml, (±10%). Nasal spray will be administered with one puff (100 microL ±10%) in one nostril (1.4 mg dose) using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
placebo, intranasal
"Same spray but without naloxone. Nasal spray will be administered with one puff (100 microL +/- 10%) in one nostril using the Aptar Unitdose device.~The spray device should be inserted about 1 cm into a nostril, pointing towards the ipsilateral ear and the plunger pushed in a firm and gentle manner for the formulation to be sprayed into the nose. After the plunger is inserted the device is immediately removed from the nose and assisted ventilation continued."
Naloxone, intramuscular
Intramuscular comparator Naloxone Hydrochloride 0.4 mg/ml will be administered as a 2 ml intramuscular (IM) injection in the deltoid muscle, total dose of 0,8 mg naloxone IM
placebo, intramuscular
Intramuscular Sodium Chloride Injection 9mg/ml, will be administered as a 2 ml intramuscular injection in the deltoid muscle
Oslo University Hospital, Prehospital devision, Oslo
St Olavs Hospital, Department for Emergency Medicine and Prehospital Services, Trondheim
St. Olavs Hospital
OTHER
Oslo University Hospital
OTHER
Norwegian University of Science and Technology
OTHER